DFW imaged

PTO/SB/21 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/583,683
Filing Date	June 19, 2006
First Named Inventor	William J. Watkins
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	01692.315US2

Total Number of Pages in This Submission

ENCLOSURES *(Check all that apply)*

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☐ Amendment/Reply
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☑ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Reply to Missing Parts/ Incomplete Application
  - ☐ Reply to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____
  - ☐ Landscape Table on CD
- ☐ After Allowance Communication to TC
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to TC **(Appeal Notice, Brief, Reply Brief)**
- ☐ Proprietary Information
- ☐ Status Letter
- ☑ Other Enclosure(s) (please Identify below):

Form 1449 (6 pgs.); Copies of 84 cited references; Return Postcard

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	VIKSNINS HARRIS & PADYS PLLP		
Signature			
Printed name	Robert J. Harris		
Date	November 1, 2006	Reg. No.	37,346

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	William J. Watkins	Examiner:	Unknown
Serial No.:	10/583,683	Group Art Unit:	Unknown
Filed:	June 19, 2006	Docket:	01692.315US2
Title:	PHOSPHONATE SUBSTITUTED KINASE INHIBITORS		

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicant requests that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication. Applicant also encloses a copy of the corresponding International Search Report for your convenience.

Pursuant to 37 C.F.R. § 1.97, no fee or statement is required with the Information Disclosure Statement. However, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 503503 in order to have this Information Disclosure Statement considered if required. The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,
William J. Watkins
By his Representatives,
Viksnins Harris & Padys PLLP
P.O. Box 111098
St. Paul, MN 55111
952 876-4092

Date 11-1-06 By _____
Robert J. Harris
Reg. No. 37,346

CERTIFICATION OF HAND DELIVERY: The undersigned certifies that this correspondence is being hand delivered to the United States Patent Office in an package addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this ____ day of November 2006.

_____ _____
Typed or Printed Name of Person Signing Certificate Signature



Substitute for form 1449A/PTO and/or 1449B/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*	*Complete if Known*	
	Application Number	10/583,683
	Filing Date	June 19, 2006
	First Named Inventor	William J. Watkins
	Group Art Unit	Unknown
	Examiner Name	Unknown
Sheet 1 of 6	01692.315US2	

US PATENT DOCUMENTS			
Examiner Initials *	**US Document Number**	**Publication Date**	**Name of Patentee/Applicant of Document**
	US 5,413,996	05-09-1995	Bodor, Nicholas S.
	US 5,670,497	09-23-1997	Bold, Guido *et al.*
	US 5,750,493	05-12-1998	Schinazi, Raymond F. *et al.*
	US 5,874,577	02-23-1999	Chen, Wei *et al.*
	US 5,914,332	06-22-1999	Chen, Xiaoqi *et al.*
	US 6,072,053	06-06-2000	Vince, Robert *et al.*
	US 6,312,662	11-06-2001	Robinson, Edward D. *et al.*
	US 5,750,343	05-12-1998	Maag, Hans *et al.*
	US 6,767,900	07-27-2004	Ubasawa, Masaru *et al.*
	US 2001-031773	10-18-2001	Camden, James Berger
	US-2003-0109498	06-12-2003	Yuasa, Satoshi *et al.*

FOREIGN PATENT DOCUMENTS			
Examiner Initials*	**Foreign Document Number (include country code)**	**Publication Date**	**Translation (Abstract Only or Full Translation, if applicable)**
	EP 0 267 050	05-11-1988	
	EP 0 441 192	01-25-1991	
	EP 0 465 297	01-08-1992	
	EP 0 531 597	03-17-1993	
	EP 0 632 048	01-04-1995	
	EP 0 786 455	07-30-1997	
	EP 0 852 233	07-08-1998	
	EP 0 919 562	06-02-1999	
	EP 1 295 879	03-26-2003	
	WO 88/06158	08-25-1988	
	WO 91/19721	12-26-1991	
	WO 92/00988	01-23-1992	
	WO 92/18520	10-29-1992	
	WO 93/12123	06-24-1993	
	WO 93/24510	12-09-1993	
	WO 96/14314	05-17-1996	
	WO 96/40156	12-19-1996	
	WO 98/04569	02-05-1998	
	WO 98/11906	03-26-1998	
	WO 99/62921	12-09-1999	
	WO 00/04033	01-27-2000	
	WO 01/13957	03-01-2001	

EXAMINER **DATE CONSIDERED**

Substitute Information Disclosure Statement Form (PTO-1449)

* Examiner: Initial if document considered, whether or not the citation is in conformance with MPEP 609. Draw line through citation if not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449A/PTO and/or 1449B/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*	*Complete if Known*	
	Application Number	10/583,683
	Filing Date	June 19, 2006
	First Named Inventor	William J. Watkins
	Group Art Unit	Unknown
	Examiner Name	Unknown
Sheet 2 of 6	01692.315US2	

FOREIGN PATENT DOCUMENTS			
Examiner Initials*	**Foreign Document Number (include country code)**	**Publication Date**	**Translation (Abstract Only or Full Translation, if applicable)**
	WO 01/17982	03-15-2001	
	WO 01/19320	03-22-2001	
	WO 01/46204	06-28-2001	
	WO 01/64693	09-07-2001	
	WO 01/96329	12-20-2001	
	WO 02/03997	01-17-2002	
	WO 02/06292	01-24-2002	
	WO 02/08241	01-31-2002	
	WO 02/14344	02-21-2002	
	WO 02/057425	07-25-2002	
	WO 02/100415	12-19-2002	
	WO 03/028737	04-10-2003	
	WO 03/050129	06-19-2003	
	WO 03/059255	07-24-2003	
	WO 03/064383	08-07-2003	
	WO 03/066005	08-14-2003	
	WO 03/080078	10-02-2003	
	WO 03/090690	11-06-2003	
	WO 2004/096234	11-11-2004	
	WO 2005/011709	02-10-2005	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	**Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source (book, magazine, journal, serial, symposium, catalog, *etc.*), Volume-Number, page(s) and (date).**
	ABDEL-MEGUID, SHERIN S. *et al.*, Inhibition of Human Immunodeficiency Virus-1 Protease by a C_2-Symmetric Phosphinate. Synthesis and Crystallographic Analysis, *Biochemistry*, 1993, 1543-1572, Vol. 32, No. 31.
	ALLEN, LEE F. *et al.*, CI-1040 (PDI84352), a Targeted Signal Transduction Inhibitor of MEK (MAPKK), *Seminars in Oncology*, October 2003, pp. 105-116, Vol. 30, No. 5, Elsevier Inc.
	BANTIA, SHANTA *et al.*, Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—a novel potent and orally active immunosuppressive agent, *International Immunopharmacology*, 2001, pp. 1199-1210, Elsevier Science B.V.
	BEAUCHAMP, LILIA M., *et al.*, Guanine, Pyrazolo[3,4-d]pyrimidine, and Triazolo[4,5-d]pyrimidine(8-Azaguanine) Phosphonate Acyclic Derivatives as Inhibitors of Purine Nucleoside Phosphorylase, *Journal of Medicinal Chemistry*, 1996, pp. 949-956, American Chemical Society.
	BOHANI D. W. *et al.*, A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection, *Bioorganic & Medicinal Chemistry Letters,* 2004, Vol. 14.

EXAMINER **DATE CONSIDERED**

Substitute for form 1449A/PTO and/or 1449B/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*	*Complete if Known*	
	Application Number	10/583,683
	Filing Date	June 19, 2006
	First Named Inventor	William J. Watkins
	Group Art Unit	Unknown
	Examiner Name	Unknown
Sheet 3 of 6	01692.315US2	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	**Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source (book, magazine, journal, serial, symposium, catalog, *etc.*), Volume-Number, page(s) and (date).**
	BZOWSKA, AGNIESZKA *et al.*, Purine nucleoside phosphorylases: properties, functions, and clinical aspects, *Pharmacology & Therapeutics*, 2000, pp. 349-425, Vol. 88, Elsevier Science Inc.
	CHAPMAN, H. *et al.*, Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro-Drug GS-7340, Nucleosides, Nucleotides & Nucleic Acids, 2001, pp. 621-628, Vol. 20, Nos. 4-7, Marcel Dekker, Inc.
	CLARK, JEREMY L. *et al.*, Mycophenolic Acid Analogues as Potential Agents Against West Nile Virus Infection.
	CONKLYN, MARYROSE *et al.*, The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing, *Journal of Leukocyte Biology*, December 2004, pp. 1-8, Vol. 76, The Society for Leukocyte Biology.
	DE CLEREQ, E., Highlights in the Development of New Antiviral Agents, *Mini Reviews in Medicinal Chemistry*, 2002, 163-175, Vol. 2, No. 2., Bentham Science Publishers, Ltd.
	DE CLERCQ, ERIK, New Developments in Anti-HIV Chemotherapy, *Current Medicinal Chemistry*, 2001, 1543-1572, Vol. 8, No. 13, Bentham Science Publishers Ltd.
	DVORAKOVA, HANA *et al.*, Synthesis of 2'-Aminomethyl Derivatives of N-(2-(Phosphonomethoxy)ethyl) Nucleotide Analogues as Potential Antiviral Agents, *J. Med. Chem.*, 1996, 3263-3268. Vol. 38, No. 17.
	EVANS, GARY B., Exploring Structure -- Activity Relationships of Transition State Analogues of Human Purine Nucleoside Phosphorylase, *J. Med. Chem.*, 2003, 3412-3423, Vol. 46, No. 15, American Chemical Society.
	GUMINA, GIUSEPPE *et al.*, Advances in antiviral agents for hepatitis B virus, *Antiviral Chemistry & Chemotherapy*, 2001, 93-112, Vol. 12, Suppl. 1, International Medical Press.
	GOBEC, S. *et al.*, Phosphonate inhibitors of antiget 85C, a crucial enzyme involved in the biosynthesis of the mycobacterium tuberculosis cell wall, *Bioorganic and Medicinal Chemistry Letters*, 2004, Vol. 14.
	HEGEDUS, LOUIS S. *et al.*, Synthesis of 4'-Methyl and 4'-cyano Carbocyclic 2',3'-Didehydro Nucleoside Analogues via 1,4-Addition to Substituted Cyclopentenones, *J. Org. Chem.*, 2004, 8492-8495, Vol. 69, No. 24, American Chemical Society.
	HERCZEGH P., *et al.*, Osteoadsorptive bisphosphonate derivatives of fluoroquinolone antibacterials, *J. Med. Chem.*, 2002, Vol. 45.
	HIRABAYASHI, HIDEKI *et al.*, Bone-Specific Drug Delivery Systems, *Clinical Pharacokinetics*, 2003, 1319-1330, Vol. 42, No. 15.
	HOLY A. *et al.*, Synthesis, *Cllect. Czech. Chem. Commun.*, 1989, Vol. 54, pages 2190-2210.
	JAIN, JUGNU *et al.*, Characterization of Pharmacological Efficacy of VX-148, a New, Potent Immunosuppressive Inosine 5'-Monophosphate Dehydrogenase Inhibitor, *Journal of Pharmacology and Experimental Therapeutics*, 2002, 1272-1277, Vol. 302, No. 3, The American Society for Pharmacology and Experimental Therapeutics.
	KARPENKO, INNA L. *et al.*, Synthesis and Antitherpetic Activity of Acyclovir Phosphonates, *NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS*, 2003, 319-328, Vol 22, No. 3, Marcel Dekker, Inc.

EXAMINER **DATE CONSIDERED**

Substitute Information Disclosure Statement Form (PTO-1449)

* Examiner: Initial if document considered, whether or not the citation is in conformance with MPEP 609. Draw line through citation if not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449A/PTO and/or 1449B/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*	*Complete if Known*	
	Application Number	10/583,683
	Filing Date	June 19, 2006
	First Named Inventor	William J. Watkins
	Group Art Unit	Unknown
	Examiner Name	Unknown
Sheet 4 of 6	01692.315US2	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	**Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source (book, magazine, journal, serial, symposium, catalog, *etc.*), Volume-Number, page(s) and (date).**
	KATO, KEISUKE *et al.*, Stereoselective synthesis of 4' -.alpha.-alkyclcarbovir derivatives based on an asymmetric synthesis or chemo-enzymatic procedure, *Chemical & Pharmaceutical Bulletin*, 1999, 1256-1264, Vol. 49, No. 9, Pharmaceutical Society of Japan.
	KATO, KEISUKE *et al.*, Enantio- and diastereoselective syntheis of 4'-α-substituted carbocyclic nucleosides, Tetrahedron: *Asymmetry*, 1998, 911-914, Vol. 9, Elsevier Science Ltd.
	KILPATRICK, J. MICHAEL, Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor, In vivo effects on blood 2'-deoxyguanosine in primates, *International Immunopharmacology*, 2003, 541-548, Vol. 3, Elsevier Science B.V.
	KIM, CHOUNG UN *et al.*, Regiospecific and Highly Stereoselective Electrophilic Addition to Furanoid Glycals: Synthesis of Phosphonate Nucleotide Analogues with Potent Activity against HIV, J. Org. Chem., 1991, 2642-2647, Vol. 56, No. 8, American Chemical Society.
	KINSKY, STEPHEN C. *et al.*, Inhibition of cell proliferation by putative metabolites and non-degradable analogs of methotrexate-.gama.-dimyristoylphosphatidylethanolamine, *Biochimica et Biphysica Acta,* 19878, 211-218, Vol. 917, No. 2., Elsevier Science Publishers B. V.
	KINSKY, STEPHEN C. *et al.*, Effect of liposomes sentitized with methotrexate-γ-dimyristoylphosphatidylethanolamine on cells that are resistant to methotrexate, *Biochimica et Biophysica Acta*, 1986, 129-135, Vol. 885, Elsevier Science Publishers B.V.
	KINSKY, STEPHEN C. *et al.*, Circumvention of the methotrexate transport system by methotrexate-phosphatidylethanolamine derivatives effect of fatty acid chain length, *Biochimica et Biophysica Acta*, 1987, 96-103, Vol. 921, Elsevier Science Publishers B.V.
	KO, OK HYUN *et al.*, Efficient synthesis of novel carbocyclic nucleosides via sequential Claisen rearrangement and ring-closing metathesis, *Tetrahedron Letters*, 2002, 6399-6402, Vol. 43, Elsevier Science Ltd.
	LEWANDOWICZ, ANDRZEJ *et al.*, Achieving the Ultimate Physiological Goal in Transition State Analogue Inhibitors for Purine Nucleoside Phosphorylase, *The Journal of Biological Chemistry*, 2003, 31465-31468, Vol. 278, No. 34, The American Society for Biochemistry and Molecular Biology, Inc.
	MENENDEZ-ARIAS, LUIS *et al.* Targeting HIV: antiretroviral therapy and development of drug resistance, *TRENDS in Pharmacological Sciences*, 2002, 381-388, Vol. 23, No. 8, Elsevier Science Ltd.
	ONO-NITA, SUZANE KIOKO *et al.*, Novel Nucleoside Analogue MCC-478 (LY582563) Is Effective against Wild-Type or Lamivudine-Resistant Hepatitis B Virus, *Antimicrobial Agents and Chemotherapy*, 2002, 2602-2605, Vol. 46, No. 8, American Society for Microbiology.
	PANKIEWICZ, KRZYSZTOF W., Novel Mycophenolic Adenine Bis(phosphonate) Analogues As Potential Differentiation Agents against Human Leukemia, *J. Med. Chem.*, 2002 703-712, Vol. 45, No. 3, American Chemical Society.
	PARANG, KEYKAVOUS *et al.*, Novel Approaches for Designing 5'-O-Ester Prodrugs of 3'-Azido-2', 3'-dideoxythymidine (AZT), *Current Medicinal Chemistry*, 2000, 995-1039, Vol. 7, No. 10, Bentham Science Publishers Ltd.
	PRASHAD, MAHAVIR *et al.*, An Efficient and Large-Scale Enantioselective Synthesis of PNP405: A Purine Nucleoside Phosphorylase Inhibitor, *J. Org. Chem.*, 2002, 6612-6617, Vol. 67, No. 19, American Chemical Society.

EXAMINER **DATE CONSIDERED**

Substitute for form 1449A/PTO and/or 1449B/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*	*Complete if Known*	
	Application Number	10/583,683
	Filing Date	June 19, 2006
	First Named Inventor	William J. Watkins
	Group Art Unit	Unknown
	Examiner Name	Unknown
Sheet 5 of 6	01692.315US2	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	**Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source (book, magazine, journal, serial, symposium, catalog, *etc.*), Volume-Number, page(s) and (date).**
	RAY, ADRIAN S. *et al.*, Role of Purine Nucleoside Phosphorylase in Interactions between 2', 3'-Dideoxyinosine and Allopurinal, Ganciclovir, or Tenofovir, Antimicrobial Agents and Chemotherapy, 2004, 1089-1095, Vol. 48, No. 4, American Society for Microbiology.
	REED, LEFF *et al.*, Antidiabetic PPARγ Ligands: An update on Compounds in development, *Curr. Med. Chem. – Imun., Endoc. & Metab. Agents*, 2002, 33-47, Vol. 2, No. 1, Bentham Science Publishers Ltd.
	ROBERTS, STANLEY M., Development of the route to the new anti-AIDS drug abacavir: A highlight of academic/industry laison, *IDrugs*, 1998, 896-899, Vol. 1, No. 8, Current Drugs Ltd.
	ROSOWSKY, ANDRE *et al.*, METHOTREXATE ANALOGUES—27, *Biochemical Pharmacology*, 1986, 3327-3333, Vol. 35, No. 19, Pergamon Journals Ltd.
	ROSOWSKY, ANDRE *et al.*, Methotrexate Analogues, 32, Chain Extension, α-Carboxyl Replacement by Sulfonate and Phosphonate: Effect on Enzyme Binding and Cell-Growth Inhibition, *J. Med. Chem.*, 1988, 1326-1331, Vol. 31, No. 7, American Chemical Society.
	SCHULTZ, C., Prodrugs of biologically active phosphate esters, *Bioorganic & Medicinal Chemistry*, 2003, 885-898, Vol. 11, Elsevier Science Ltd., GB.
	SEKIYA, KOUICHI *et al.*, 2-Amino-6-arylthio-9-[2-(phosphonomethoxy) ethyl) purine Bis(2,2,2-trifluoroethyl) Esters as Novel HBV-Specific Antiviral Reagents, Journal of Medicinal Chemistry, 2002, 3138-3142, Vol. 45, No. 14, American Chemical Society.
	SHI, WUXIAN *et al.*, *Plasmodium falciparum* Purine Nucleoside Phosphorylase, The Journal of Biological Chemistry, 2004, 18103-18106, Vol. 279, No. 18, The American Society of Biochemistry and Molecular Biology, Inc.
	SINTCHAK, MICHAEL D. *et al.*, The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors, Immunopharmachology, 2000, 163-184, Vol. 47, Elsevier.
	SRINIVAS, RANGA V. *et al.*, Metabolism and In Vitro Antiretroviral Activities of Bis(Pivaloyloxymethyl) Prodrugs of Acyclic Nucleoside Phosphonates, Antimicrobial Agents and Chemotherapy, 1993, 2247-2250, Vol. 37, No. 10, American Society for Microbiology.
	STURTZ, GEORGES *et al.*, Su rune nouvelle approche de pharmacomodulation du methotrexate: synthese d'analogues gem-diphosphoniques d'amethopterine et de la N-10 deaza amethopterine, Medicinal Chemistry, C. R. Acad. Sci. Paris, 1990, Vol. 10, No. 2, 739-742, Academie des Sciences.
	STURTZ, GEORGES *et al.*, Analogues phosphonoglutamiques d'amethopterine (methotrexate), Eur. J. Med. Chem – Chim. Ther., 1984, 267-273, Vol. 19, No. 3.
	STURTZ, G. *et al.*, Synthesis of gem-bisphosphonic methotrexate conjugates and their biological response towards Walker's osteosarcoma, *Eur. J. Med. Chem.*, 1993, 899-903, Vol. 28, Elsevier.
	STURTZ, G. *et al.*, A study of the delivery-targeting concept applied to antineoplasic drugs active on human osteosarcoma, I. Synthesis and biological activity in nude mice carrying human osteosarcoma xenografts of gem-bisphosphonic methotrexate analogues, Eur J. Med. Chem., 1992, 825-833, Vol. 27, No. 8, Elsevier.
	VIELHABER, BERND, Bericht vom 3rd International Workshop on Salvage Therapy for HIV-Infection, *Deutsche Aids-Hilfe e.V. FaxReport zu HIV und AIDS,* 2000, 12-14.
	WAEGELL W. *et al.* A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection, Transplantation Proceedings, 2002, 1411-1417, Vol. 34.

EXAMINER **DATE CONSIDERED**

Substitute for form 1449A/PTO and/or 1449B/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*	*Complete if Known*	
	Application Number	10/583,683
	Filing Date	June 19, 2006
	First Named Inventor	William J. Watkins
	Group Art Unit	Unknown
	Examiner Name	Unknown
Sheet 6 of 6	01692.315US2	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	**Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source (book, magazine, journal, serial, symposium, catalog, *etc.*), Volume-Number, page(s) and (date).**
	WROBLEWSKI, ANDRZEJ *et al.*, Synthesis of (1R,2S)- and (1S,2S)-3-(4-carbamoyl-1,2,3-triazol-1-yl)-1,2-dihydroxypropylphosphonates, Tetrahedron: Asymmetry, 2004, 1457-1464, Vol. 15, Elsevier.

EXAMINER **DATE CONSIDERED**

Substitute Information Disclosure Statement Form (PTO-1449)

* Examiner: Initial if document considered, whether or not the citation is in conformance with MPEP 609. Draw line through citation if not considered. Include copy of this form with next communication to Applicant.